Phellodendron and Citrus extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study
Identifieur interne : 000A38 ( Ncbi/Checkpoint ); précédent : 000A37; suivant : 000A39Phellodendron and Citrus extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study
Auteurs : Julius Oben [Cameroun] ; Ebangha Enonchong [Cameroun] ; Shil Kothari [États-Unis] ; Walter Chambliss [États-Unis] ; Robert Garrison [États-Unis] ; Deanne Dolnick [États-Unis]Source :
- Nutrition Journal [ 1475-2891 ] ; 2009.
English descriptors
- KwdEn :
- Adult, C-Reactive Protein (metabolism), Citrus (chemistry), Dietary Supplements, Double-Blind Method, Female, Humans, Joints (drug effects), Male, Middle Aged, Osteoarthritis (drug therapy), Overweight (drug therapy), Phellodendron (chemistry), Pilot Projects, Plant Extracts (administration & dosage), Plant Extracts (therapeutic use).
- MESH :
- chemical , administration & dosage : Plant Extracts.
- chemical , metabolism : C-Reactive Protein.
- chemistry : Citrus, Phellodendron.
- drug effects : Joints.
- drug therapy : Osteoarthritis, Overweight.
- chemical , therapeutic use : Plant Extracts.
- Adult, Dietary Supplements, Double-Blind Method, Female, Humans, Male, Middle Aged, Pilot Projects.
Abstract
The objective of this clinical study was to assess the potential benefit of a dietary supplement, NP 06-1, on joint health in overweight and normal weight adults diagnosed with osteoarthritis.
An 8-week placebo-controlled, randomized, double-blind study was conducted with four groups comparing the effects of NP 06-1 to placebo on overweight and normal weight subjects diagnosed with primary osteoarthritis of the knee. NP 06-1 (a combination of two botanical extracts;
Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were reported. The mean total LAI scores at baseline for the four groups ranged from 11.4 to 12.4 (SD 1.2 to 2.4). Treatment for 8 weeks resulted in a statistical improvement in the LAI score in the overweight treatment group compared to placebo (6.3 ± 2.3 vs 11.8 ± 1.5; p < 0.0001). At 8 weeks, a similar result was observed in the normal weight groups (7.7 ± 1.4 vs 9.9 ± 0.9; p < 0.0001). There was a reduction in CRP levels with treatment in the overweight treatment group at 8 weeks (-0.62 ± 0.2; 49%) compared to baseline (p < 0.001) and to placebo (p < 0.001). For the normal weight participants, there were significant reductions in CRP compared to baseline, but not to the matched placebo group. Both overweight and normal weight treatment groups lost a significant amount of weight compared to their placebo groups. The overweight treatment group lost an average of 5% body weight after 8 weeks. There was no significant change in ESR in any of the groups.
In this pilot study, NP 06-1 had beneficial effects on symptoms of osteoarthritis of the knee as measured using LAI scores and had anti-inflammatory effects as measured using CRP. Administration of NP 06-1 was also associated with weight loss, which may have been a contributing factor to the other benefits.
Url:
DOI: 10.1186/1475-2891-8-38
PubMed: 19682376
PubMed Central: 2739863
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000989
- to stream Pmc, to step Curation: 000988
- to stream Pmc, to step Checkpoint: 001041
- to stream PubMed, to step Corpus: 000934
- to stream PubMed, to step Curation: 000934
- to stream PubMed, to step Checkpoint: 000934
- to stream Ncbi, to step Merge: 000A38
- to stream Ncbi, to step Curation: 000A38
Links to Exploration step
PMC:2739863Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en"><italic>Phellodendron </italic>and <italic>Citrus </italic>extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study</title><author><name sortKey="Oben, Julius" sort="Oben, Julius" uniqKey="Oben J" first="Julius" last="Oben">Julius Oben</name><affiliation wicri:level="1"><nlm:aff id="I1">Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon</nlm:aff><country xml:lang="fr">Cameroun</country><wicri:regionArea>Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I</wicri:regionArea><wicri:noRegion>University of Yaounde I</wicri:noRegion></affiliation></author><author><name sortKey="Enonchong, Ebangha" sort="Enonchong, Ebangha" uniqKey="Enonchong E" first="Ebangha" last="Enonchong">Ebangha Enonchong</name><affiliation wicri:level="1"><nlm:aff id="I1">Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon</nlm:aff><country xml:lang="fr">Cameroun</country><wicri:regionArea>Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I</wicri:regionArea><wicri:noRegion>University of Yaounde I</wicri:noRegion></affiliation></author><author><name sortKey="Kothari, Shil" sort="Kothari, Shil" uniqKey="Kothari S" first="Shil" last="Kothari">Shil Kothari</name><affiliation wicri:level="2"><nlm:aff id="I2">Gateway Health Alliances, Inc., 4769 Mangels Blvd, Fairfield, CA 94534 USA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gateway Health Alliances, Inc., 4769 Mangels Blvd, Fairfield</wicri:cityArea></affiliation></author><author><name sortKey="Chambliss, Walter" sort="Chambliss, Walter" uniqKey="Chambliss W" first="Walter" last="Chambliss">Walter Chambliss</name><affiliation wicri:level="2"><nlm:aff id="I3">University of Mississippi, University, MS 38677 USA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État du Mississippi</region></placeName><wicri:cityArea>University of Mississippi, University</wicri:cityArea></affiliation></author><author><name sortKey="Garrison, Robert" sort="Garrison, Robert" uniqKey="Garrison R" first="Robert" last="Garrison">Robert Garrison</name><affiliation wicri:level="2"><nlm:aff id="I4">Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA 93907 USA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Next Pharmaceuticals, 360 Espinosa Road, Salinas</wicri:cityArea></affiliation></author><author><name sortKey="Dolnick, Deanne" sort="Dolnick, Deanne" uniqKey="Dolnick D" first="Deanne" last="Dolnick">Deanne Dolnick</name><affiliation wicri:level="2"><nlm:aff id="I4">Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA 93907 USA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Next Pharmaceuticals, 360 Espinosa Road, Salinas</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19682376</idno><idno type="pmc">2739863</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739863</idno><idno type="RBID">PMC:2739863</idno><idno type="doi">10.1186/1475-2891-8-38</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">000989</idno><idno type="wicri:Area/Pmc/Curation">000988</idno><idno type="wicri:Area/Pmc/Checkpoint">001041</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000934</idno><idno type="wicri:Area/PubMed/Curation">000934</idno><idno type="wicri:Area/PubMed/Checkpoint">000934</idno><idno type="wicri:Area/Ncbi/Merge">000A38</idno><idno type="wicri:Area/Ncbi/Curation">000A38</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main"><italic>Phellodendron </italic>and <italic>Citrus </italic>extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study</title><author><name sortKey="Oben, Julius" sort="Oben, Julius" uniqKey="Oben J" first="Julius" last="Oben">Julius Oben</name><affiliation wicri:level="1"><nlm:aff id="I1">Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon</nlm:aff><country xml:lang="fr">Cameroun</country><wicri:regionArea>Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I</wicri:regionArea><wicri:noRegion>University of Yaounde I</wicri:noRegion></affiliation></author><author><name sortKey="Enonchong, Ebangha" sort="Enonchong, Ebangha" uniqKey="Enonchong E" first="Ebangha" last="Enonchong">Ebangha Enonchong</name><affiliation wicri:level="1"><nlm:aff id="I1">Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Cameroon</nlm:aff><country xml:lang="fr">Cameroun</country><wicri:regionArea>Laboratory of Nutrition & Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I</wicri:regionArea><wicri:noRegion>University of Yaounde I</wicri:noRegion></affiliation></author><author><name sortKey="Kothari, Shil" sort="Kothari, Shil" uniqKey="Kothari S" first="Shil" last="Kothari">Shil Kothari</name><affiliation wicri:level="2"><nlm:aff id="I2">Gateway Health Alliances, Inc., 4769 Mangels Blvd, Fairfield, CA 94534 USA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Gateway Health Alliances, Inc., 4769 Mangels Blvd, Fairfield</wicri:cityArea></affiliation></author><author><name sortKey="Chambliss, Walter" sort="Chambliss, Walter" uniqKey="Chambliss W" first="Walter" last="Chambliss">Walter Chambliss</name><affiliation wicri:level="2"><nlm:aff id="I3">University of Mississippi, University, MS 38677 USA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État du Mississippi</region></placeName><wicri:cityArea>University of Mississippi, University</wicri:cityArea></affiliation></author><author><name sortKey="Garrison, Robert" sort="Garrison, Robert" uniqKey="Garrison R" first="Robert" last="Garrison">Robert Garrison</name><affiliation wicri:level="2"><nlm:aff id="I4">Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA 93907 USA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Next Pharmaceuticals, 360 Espinosa Road, Salinas</wicri:cityArea></affiliation></author><author><name sortKey="Dolnick, Deanne" sort="Dolnick, Deanne" uniqKey="Dolnick D" first="Deanne" last="Dolnick">Deanne Dolnick</name><affiliation wicri:level="2"><nlm:aff id="I4">Next Pharmaceuticals, 360 Espinosa Road, Salinas, CA 93907 USA</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Next Pharmaceuticals, 360 Espinosa Road, Salinas</wicri:cityArea></affiliation></author></analytic><series><title level="j">Nutrition Journal</title><idno type="eISSN">1475-2891</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>C-Reactive Protein (metabolism)</term><term>Citrus (chemistry)</term><term>Dietary Supplements</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Joints (drug effects)</term><term>Male</term><term>Middle Aged</term><term>Osteoarthritis (drug therapy)</term><term>Overweight (drug therapy)</term><term>Phellodendron (chemistry)</term><term>Pilot Projects</term><term>Plant Extracts (administration & dosage)</term><term>Plant Extracts (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Plant Extracts</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>C-Reactive Protein</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Citrus</term><term>Phellodendron</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Joints</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Osteoarthritis</term><term>Overweight</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Plant Extracts</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dietary Supplements</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>The objective of this clinical study was to assess the potential benefit of a dietary supplement, NP 06-1, on joint health in overweight and normal weight adults diagnosed with osteoarthritis.</p></sec><sec sec-type="methods"><title>Methods</title><p>An 8-week placebo-controlled, randomized, double-blind study was conducted with four groups comparing the effects of NP 06-1 to placebo on overweight and normal weight subjects diagnosed with primary osteoarthritis of the knee. NP 06-1 (a combination of two botanical extracts; <italic>Phellodendron amurense </italic>bark and <italic>Citrus sinensis </italic>peel) or matching placebo were given in a dose of two capsules (370 mg each) twice daily. The outcome measures were the Lequesne Algofunctional Index (LAI) for joint pain and movement as well as biomarkers of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]).</p></sec><sec><title>Results</title><p>Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were reported. The mean total LAI scores at baseline for the four groups ranged from 11.4 to 12.4 (SD 1.2 to 2.4). Treatment for 8 weeks resulted in a statistical improvement in the LAI score in the overweight treatment group compared to placebo (6.3 ± 2.3 vs 11.8 ± 1.5; p < 0.0001). At 8 weeks, a similar result was observed in the normal weight groups (7.7 ± 1.4 vs 9.9 ± 0.9; p < 0.0001). There was a reduction in CRP levels with treatment in the overweight treatment group at 8 weeks (-0.62 ± 0.2; 49%) compared to baseline (p < 0.001) and to placebo (p < 0.001). For the normal weight participants, there were significant reductions in CRP compared to baseline, but not to the matched placebo group. Both overweight and normal weight treatment groups lost a significant amount of weight compared to their placebo groups. The overweight treatment group lost an average of 5% body weight after 8 weeks. There was no significant change in ESR in any of the groups.</p></sec><sec><title>Conclusion</title><p>In this pilot study, NP 06-1 had beneficial effects on symptoms of osteoarthritis of the knee as measured using LAI scores and had anti-inflammatory effects as measured using CRP. Administration of NP 06-1 was also associated with weight loss, which may have been a contributing factor to the other benefits.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Cameroun</li><li>États-Unis</li></country><region><li>Californie</li><li>État du Mississippi</li></region></list><tree><country name="Cameroun"><noRegion><name sortKey="Oben, Julius" sort="Oben, Julius" uniqKey="Oben J" first="Julius" last="Oben">Julius Oben</name></noRegion><name sortKey="Enonchong, Ebangha" sort="Enonchong, Ebangha" uniqKey="Enonchong E" first="Ebangha" last="Enonchong">Ebangha Enonchong</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Kothari, Shil" sort="Kothari, Shil" uniqKey="Kothari S" first="Shil" last="Kothari">Shil Kothari</name></region><name sortKey="Chambliss, Walter" sort="Chambliss, Walter" uniqKey="Chambliss W" first="Walter" last="Chambliss">Walter Chambliss</name><name sortKey="Dolnick, Deanne" sort="Dolnick, Deanne" uniqKey="Dolnick D" first="Deanne" last="Dolnick">Deanne Dolnick</name><name sortKey="Garrison, Robert" sort="Garrison, Robert" uniqKey="Garrison R" first="Robert" last="Garrison">Robert Garrison</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Bois/explor/OrangerV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000A38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Bois
|area= OrangerV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= PMC:2739863
|texte= Phellodendron and Citrus extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:19682376" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a OrangerV1
| This area was generated with Dilib version V0.6.25. |  |